Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recifercept - Pfizer

Next Previous
Drug Profile

Recifercept - Pfizer

Alternative Names: PF-07256472; Reciferecept; TA-46

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therachon
  • Developer Pfizer
  • Class Proteins; Recombinant proteins
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Achondroplasia

Most Recent Events

  • 18 Apr 2023 Pfizer withdraws a phase I trial in healthy adult volunteers in China (SC) before enrolment due to corporate strategic considerations (NCT05061277)
  • 27 Mar 2023 Pfizer terminates a phase II trial in Achondroplasia (In infants, In children) in US, Australia, Belgium, Denmark, Italy, Japan, Portugal and Spain (SC), due to lack of efficacy at any of the tested doses(NCT04638153)
  • 03 Feb 2023 Discontinued - Phase-II for Achondroplasia (In children, In infants) in Japan, Italy, USA, Australia (SC) (Pfizer pipeline, February 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top